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ABSTRACT
Introduction: Patients with major depressive
disorder (MDD) often fail to respto first-line
antidepressant treatments (ADTs); subsequent
strategies include dosage increase, switch to a
different ADT, or addition of another ADT or
other drug. The objective of this prospective,
case review study was to identify factors that
influence the decision to prescribe adjunctive
antipsychotics for patients with MDD and
inadequate response to ADT.
Methods: Psychiatrists or primary care
physicians (n = 411) based in the USA and
Europe each completed an online survey for
ten consecutive adults with MDD and
inadequate response to ADTs, and for whom a
treatment change was considered. A t test was
used to compare survey responses between
groups of patients.
Results: The survey was completed for 4018
patients; an adjunctive antipsychotic was
considered for 961/4018 patients (23.9%) and
actually prescribed for 514/4018 (12.8%).
Compared with patients not considered for an
adjunctive antipsychotic, those who were
considered for this treatment had more
previous major depressive episodes (MDEs),
longer duration of the current MDE, more
severe illness both at ADT initiation and
current consultation, and more treatment
changes. Patients who were prescribed
adjunctive antipsychotics had at baseline more
functional impairment and absences from work
than those considered for but not prescribed this
treatment. Key symptoms that prompted
physicians to consider antipsychotics were
psychotic symptoms, psychomotor agitation,
hostility, irritability, impulsivity, and anger
bursts. Anxious mood and irritability were
mentioned significantly more often by
physicians who actually prescribed adjunctive
antipsychotics. Obstacles to prescribing
included a tendency to wait to see if symptoms
improved and concern over side effects.
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Conclusion: This real-world study suggested
that the decision to prescribe an adjunctive
antipsychotic for patients with MDD and
inadequate response to ADT is influenced by a
broad spectrum of factors, predominantly
related to severity of illness, functional
impairment, and symptom profile.
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INTRODUCTION
Despite the availability of a range of
antidepressant treatments (ADTs), many
patients with major depressive disorder (MDD)
only have a partial response to first-line
therapies [1, 2]. An inadequate response is
more likely to occur in patients with a longer
duration of illness, more severe symptoms and
comorbid illnesses [3]. Since incomplete
remission is associated with an increased risk
of relapse, impaired work and social
functioning, and an increased risk of suicide
[3], it is important that patients with an
inadequate response are both promptly
identified and prescribed an effective course of
treatment.
Identification of patients with inadequate
response can be achieved via the use of
standardized and validated measurement tools,
so that modifications to treatment, including
dosage increases, changing ADT, or the addition
of an adjunctive treatment, can be promptly
implemented. Augmentation of treatment with
adjunctive therapies can be either another ADT
of the same or different class (combination
therapy), or a new therapeutic approach such as
administration of a second-generation
antipsychotic [1, 4, 5] which has been shown
to improve the clinical response rate at 6 weeks
in patients with MDD refractory to ADT by as
much as 50% [6]. However, second-generation
antipsychotics are frequently associated with
intolerable side effects [7, 8].
With increasing numbers of both ADTs and
second-generation antipsychotics indicated for
use in MDD, the absence of evidence-based
guidelines and lack of high-quality data [9]
complicates the choice of adjunctive drug for
patients with an inadequate response to
monotherapy. The choice of treatment for any
individual patient may depend on factors such
as symptomatology, disease and treatment
history, and patient preference. A retrospective
study on choice of adjunctive treatment
reported that augmentation of ADT with a
second-generation antipsychotic was more
likely in patients with the most severe
depression [10].
The objective of this case review study was to
examine real-world data from patient records to
identify the key factors that influence the
treatment decision for patients with MDD and
an inadequate response to ADT.
METHODS
Study Design
This chart review study was designed to be
prospective and was conducted in the USA and
Europe between February and April 2014.
Physicians invited to participate were
psychiatrists or primary care physicians (USA
only) who had been qualified for between
3 and 40 years and were actively managing
and treating patients with MDD. An
appropriate caseload was considered to be at
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least 20 patients with MDD in a typical month.
The physicians were recruited from a specialist
market research panel and their qualifications
were subsequently verified. Physicians were
invited to take part by email and those who
responded answered several screening
questions to ensure that they met the
inclusion criteria. Physicians were selected to
provide a balance of hospital- versus office-
based and public versus private psychiatrists
with a representative spread within key
geographic regions.
Physicians were asked to complete an online
survey that was divided into three sections (see
the electronic supplementary material). Section
A was designed to collect information about the
physician, and estimates or perceptions of their
caseload and general clinical management of
patients with MDD. Section Bi was
prospectively completed for ten consecutive
adults, who the physician considered to have a
diagnosis of MDD, who were being treated with
ADTs for a current major depressive episode
(MDE), who had an inadequate response, and
for whom the physician considered or made a
treatment change at the current consultation.
Since the study objective was to understand the
real-world clinical practice, International
Classification of Diseases (ICD) or Diagnostic
and Statistical Manual of Mental Disorders
(DSM) diagnostic criteria were not specified as
part of the patient selection process. Towards
the end of recruitment, the protocol was
modified so that physicians could complete
the survey for between five and ten patients.
Section Bii was only completed for patients for
whom treatment with an adjunctive
antipsychotic was considered or prescribed.
Sections Bi and Bii were completed using
information from the consultation and patient
record forms on the day of consultation, or as
soon as possible afterwards.
Section Bi comprised questions on the
patient’s socio-demographic characteristics,
disease and treatment history, duration and
severity of current MDE (based on Clinical
Global Impression-Severity [CGI-S]),
comorbidities, current treatment, change to
treatment regimen considered or initiated at
current consultation, reasons for prescribing the
new treatment, and barriers to the use of
adjunctive antipsychotics in this patient.
Physicians who indicated that they preferred
to reserve antipsychotics for specific symptoms
were asked to select from a checklist the
symptoms that would trigger prescription of
this class of drug. Physicians who stated they
had tolerability or safety concerns that
prevented them from adding an antipsychotic
for a particular patient were asked to identify
their concerns from a checklist.
Section Bii included questions on which
factors had led to prescription or consideration
of adjunctive antipsychotics for each patient.
Questions regarding symptoms that led to
adjunctive antipsychotic prescribing were
presented randomly to half the physicians as a
symptom checklist (coded) and half as an open
text box (open) to evaluate any potential effect
of prompted compared with non-elicited
responses.
The analysis in this article is based on patient
record forms, in the form of market research
with physician and patient anonymity
preserved entirely, and does not involve any
new studies with human or animal subjects
performed by any of the authors. Consequently,
institutional review board approval and patient
informed consent were not required.
Statistical Analysis
Data relating to patients have been summarized
for: all patients (Bi); patients for whom an
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adjunctive antipsychotic was considered or
actually prescribed (Bii: adjunctive
antipsychotic group); and patients for whom
an adjunctive antipsychotic was not considered
or prescribed (Bi - Bii: non-adjunctive
antipsychotic group).
Statistical analyses were: demographic and
disease characteristics for the adjunctive
antipsychotic-considered and adjunctive
antipsychotic-prescribed groups compared
with the non-adjunctive antipsychotic group;
employment status, absenteeism, presenteeism
and impact on social functioning parameters
compared between the adjunctive
antipsychotic-considered and adjunctive
antipsychotic-prescribed groups; symptoms
that triggered prescription of antipsychotics
compared between physicians who did not
and did actually prescribe this treatment to
patients in the survey; comparison of symptoms
captured using the coded and open formats
(where open questions were coded up into
categories so that these could be treated as
quantitative data). All statistical comparisons




The survey was completed by 411 physicians
located in the USA (129, 31.4%), France (58,
14.1%), UK (57, 13.9%), Italy (56, 13.6%), Spain
(56, 13.6%), and Germany (55, 13.4%). The
majority of physicians were psychiatrists (343/
411, 83.5%), while the remainder were primary
care physicians (68/411, 16.6%). Respondents
had been qualified for a median of 15 years,
dividing into experience groups of 3–10 years
(101/411, 24.6%), 11–20 years (209/411, 50.9%)
or C21 years (101/411, 24.6%). The physicians
reported that over 90% of their time, on
average, was spent actively treating patients.
In a typical month, they saw an average of 98
adults with MDD, around half of whom (47)
were inadequately responding to ADT. On
average, physicians estimated that 81.9% of
their patients with MDD were receiving
treatment for an acute episode, comprising
41.1% who were responding adequately,
19.8% with some unresolved symptoms but
not requiring a change to their treatment
regimen, and 21.0% with an inadequate
response that did require a treatment
change. The remaining patients (18.1%) were
receiving maintenance therapy to prevent
further relapse.
Treatments
Physicians completed the survey for a total of
4018 patients whom they identified as having
MDD and an inadequate response to current
treatment. Prior to the current consultation,
1880/4018 patients (46.8%) were receiving
monotherapy, mostly with an ADT (1766/
4018, 44.0%), and 2137/4018 patients (53.2%)
were on combination therapy (see Table 1). The
combinations most frequently mentioned were
an ADT with a benzodiazepine (492/4018,
12.2%) or an ADT with an antipsychotic (294/
4018, 7.3%). Other combinations (860/4018,
21.4%) comprised various combinations of
three or more drugs. Antipsychotics were
being prescribed to 40/4018 patients (1.0%) as
monotherapy and 294/4018 (7.3%) as an
adjunctive to an ADT.
At the current consultation, physicians were
most likely to switch the ADT to a different drug
or add a new adjunctive drug (see Table 2). A
treatment change involving an adjunctive
antipsychotic was considered for 961/4018
patients (23.9%). Around half of these patients
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were actually prescribed an adjunctive
antipsychotic (514/4018, 12.8%). This was
prescribed as a new adjunctive drug for
343/4018 patients (8.5%) and as a switch of an
existing adjunctive drug for 173/4018 patients
(4.3%). Two patients were each prescribed two
new adjunctive antipsychotics and one patient
was prescribed a new adjunctive antipsychotic
and was switched from a currently prescribed
drug to an antipsychotic. In addition,
antipsychotic monotherapy was newly
prescribed for 55/4018 patients (1.4%).
Physicians appeared to be more likely to
consider prescribing or actually prescribe
adjunctive antipsychotics for patients who
were already on combination therapy than
those on monotherapy (see Table 1).
When considering the influence of physician
experience on this treatment decision,
experienced physicians ([15 years in practice,
based on median experience) prescribed
adjunctive antipsychotics in 242/1779 (13.6%)
patients compared with 272/2239 (12.2%)
patients prescribed adjunctive antipsychotics
Table 1 Current pharmacological treatment




(N5 4018)Considered (n 5 447) Prescribed (n5 514)
Monotherapy 129 (28.9) 172 (33.5) 1579 (51.7) 1880 (46.8)
SSRI 81 (18.1) 98 (19.1) 1017 (33.3) 1196 (29.8)
SNRI 23 (5.1) 44 (8.6) 292 (9.6) 359 (8.9)
Tricyclic 6 (1.3) 7 (1.4) 46 (1.5) 59 (1.5)
Other ADT 13 (2.9) 13 (2.5) 126 (4.1) 152 (3.8)
Hypnotic/anxiolytic 0 (0.0) 1 (0.2) 26 (0.9) 27 (0.7)
Atypical AP 3 (0.7) 5 (1.0) 32 (1.0) 40 (1.0)
Otherb 3 (0.7) 4 (0.8) 40 (1.3) 47 (1.2)
Combination therapy 318 (71.1) 342 (66.5) 1477 (48.3) 2137 (53.2)
2 ADTs 32 (7.2) 25 (4.9) 169 (5.5) 226 (5.6)
ADT ? BZ 52 (11.6) 63 (12.3) 377 (12.3) 492 (12.2)
ADT ? AP 45 (10.1) 60 (11.7) 189 (6.2) 294 (7.3)
ADT ?MS 9 (2.0) 4 (0.8) 36 (1.2) 49 (1.2)
ADT ? otherb 19 (4.3) 24 (4.7) 173 (5.7) 216 (5.4)
Other combinationc 161 (36.0) 166 (32.3) 533 (17.4) 860 (21.4)
No drug treatment 0 (0.0) 0 (0.0) 1 (0.03) 1 (0.02)
ADT Antidepressant treatment, AP antipsychotic, BZ benzodiazepine, MS mood stabilizer, SNRI serotonin noradrenaline
reuptake inhibitor, SSRI selective serotonin reuptake inhibitor
a Patients for whom the physician considered prescribing or prescribed an adjunctive antipsychotic, either as a new
adjunctive treatment or as a switch from the patient’s current adjunctive treatment
b Other drugs included lithium, valproate, St John’s wort, and other pharmacological treatments
c Various combinations of three or more drugs
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by less experienced physicians. When this was
re-examined for a cut-point of more or less than
10 years’ experience, the difference remained
marginal, with a reversed numerical difference
(12.4% versus 13.8%, respectively), suggesting
experience did not affect the decision to
prescribe adjunctive antipsychotics. It was also
unaffected by region; US physicians prescribed
for 166/1198 (13.9%) patients, compared with
348/2820 (12.3%) patients prescribed
adjunctive antipsychotics by European
physicians.
Patient Demographics and Disease History
The study population was spread across all age
categories from 18–24 years to C65 years (see
Table 3). Slightly more than half of the patients
were female. Compared with patients who
were not considered for an adjunctive
antipsychotic, there was some evidence that
those who were considered for or prescribed
this treatment had more previous MDEs, longer
duration of the current MDE, greater CGI-S
score both at ADT initiation and the current
consultation, and more previous treatment
changes (see Table 3).
Employment Status and Patient
Functioning
Data regarding employment status and patient
functioning were collected for patients who
were considered for but not prescribed an
adjunctive antipsychotic and those who were
prescribed an adjunctive antipsychotic.
Employment status was similar in both groups:
among patients who were prescribed an
adjunctive antipsychotic, 109/514 (21.2%)
were working full-time and 79/514 (15.4%)
were working part-time, compared with
91/446 (20.4%) and 58/446 (13.0%),
respectively, in those considered for an
adjunctive antipsychotic. However,
absenteeism was significantly higher in those
who were prescribed compared with those who
were considered for an adjunctive antipsychotic
(prescribed: n = 154, mean 12.2 days/month
versus considered: n = 128, mean
9.3 days/month; P\0.05). Additionally, the
number of days/month during which patients
did not perform their usual daily tasks at their
usual level (presenteeism) was significantly
higher in patients prescribed than those
considered for an adjunctive antipsychotic
Table 2 Treatment changes at current consultation




(N5 4018)Considered (n5 447) Prescribed (n5 514)
Switch antidepressant drug 243 (54.4) 94 (18.3) 1176 (38.5) 1513 (37.7)
New adjunctive drugc 113 (25.3) 366 (71.2) 763 (25.0) 1242 (30.9)
Switch adjunctive drug 29 (6.5) 190 (37.0) 445 (14.6) 664 (16.5)
Other action, e.g., dose change 106 (23.7) 8 (1.6) 972 (31.8) 1086 (27.0)
a Patients for whom the physician considered prescribing or prescribed an adjunctive antipsychotic, either as a new
adjunctive treatment or as a switch from the patient’s current adjunctive treatment
b Patients may have had more than one type of treatment change
c Including antidepressant drugs, hypnotics, anxiolytics, atypical antipsychotics, lithium, valproate, St John’s wort, and other
drugs
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18–24 years 49 (11.0) 48 (9.3) 341 (11.2) 438 (10.9)
25–34 years 73 (16.3) 94 (18.3) 637 (20.8) 804 (20.0)
35–44 years 77 (17.2) 107 (20.8) 622 (20.4) 806 (20.1)
45–54 years 115 (25.7)b 123 (23.9) 633 (20.7) 871 (21.7)
55–64 years 73 (16.3) 81 (15.8) 494 (16.2) 648 (16.1)
C65 years 60 (13.4) 61 (11.9) 330 (10.8) 451 (11.2)
Mean, years 45.6b 44.7 43.8 44.1
Gender, n (%)
Male 187 (41.8) 241 (46.9)b 1287 (42.1) 1715 (42.7)
Female 260 (58.2) 273 (53.1) 1770 (57.9) 2303 (57.3)
Age of onset of ﬁrst MDE, n (%) (n = 405) (n = 471) (n = 2840) (n = 3716)
18–24 years 114 (28.2) 111 (23.6) 715 (25.2) 940 (25.3)
25–34 years 121 (29.9) 160 (34.0) 906 (31.9) 1187 (31.9)
35–44 years 75 (18.5) 94 (20.0) 601 (21.2) 770 (20.7)
45–54 years 54 (13.3) 60 (12.7) 324 (11.4) 438 (11.8)
55–64 years 23 (5.7) 26 (5.5) 186 (6.6) 235 (6.3)
C65 years 18 (4.4) 20 (4.3) 108 (3.8) 146 (3.9)
Mean, years 32.4 33.2 33.1 33.0
Number of MDEs since diagnosis, n (%)
1 67 (15.0) 89 (17.3) 824 (27.0) 980 (24.4)
2 110 (24.6) 129 (25.1) 797 (26.1) 1036 (25.8)
3 94 (21.0) 101 (19.7) 542 (17.7) 737 (18.3)
4 46 (10.3) 58 (11.3)b 256 (8.4) 360 (9.0)
C5 130 (29.1)b 137 (26.7)b 638 (20.9) 905 (22.5)
Mean 4.3b 3.7 3.6 3.7
Duration of current MDE, n (%)
\1 month 62 (13.9) 69 (13.4) 532 (17.4) 663 (16.5)
1–3 months 159 (35.6) 208 (40.5) 1215 (39.7) 1582 (39.4)
3–6 months 145 (32.4)b 155 (30.2) 822 (26.9) 1122 (27.9)
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(prescribed: n = 376, mean 17.4 days/month
versus considered: n = 317, mean 13.9 days/
month; P\0.05).
Physicians considered MDD to have a great
impact on family relationships in a significantly














6–9 months 28 (6.3) 40 (7.8) 168 (5.5) 236 (5.9)
9–12 months 27 (6.0) 25 (4.9) 168 (5.5) 220 (5.5)
C12 months 26 (5.8) 17 (3.3) 152 (5.0) 195 (4.9)
Mean, months 5.5b 4.6 4.9 5.0
CGI-S score, n (%)
At ADT initiation
Mild (1–2) 7 (1.6) 7 (1.4) 55 (1.8) 69 (1.7)
Moderate (3–5) 270 (60.4) 294 (57.2) 2198 (71.9) 2762 (68.7)
Severe (6–7) 166 (37.1)b 208 (40.5)b 759 (24.8) 1133 (28.2)
Unknown 4 (0.9) 5 (1.0) 45 (1.5) 54 (1.3)
Today
Mild (1–2) 66 (14.8) 60 (11.7) 691 (22.6) 817 (20.3)
Moderate (3–5) 338 (75.6) 380 (73.9) 2196 (71.8) 2914 (72.5)
Severe (6–7) 43 (9.6)b 74 (14.4)b 170 (5.6) 287 (7.1)
Comorbidities, n (%)
None 55 (12.3) 74 (14.4) 572 (18.7) 701 (17.5)
Any psychiatric comorbidityc 220 (49.2) 276 (53.7) 1279 (41.8) 1775 (44.2)
Any somatic comorbidityc 306 (68.5) 339 (66.0) 1819 (59.5) 2464 (61.3)
No current non-pharmacological treatment, n (%) 159 (35.6) 176 (34.2) 1270 (41.5) 1605 (40.0)
Mean number of previous treatment changes 5.3b 4.9b 3.7 4.0
ADT Antidepressant treatment, CGI-S clinical global impression-severity, MDE major depressive episode
a Patients for whom the physician considered prescribing or prescribed an adjunctive antipsychotic
b P\0.05 versus non-adjunctive antipsychotic group (patients who were not considered for or prescribed an adjunctive
antipsychotic)
c Psychiatric comorbidities included generalized anxiety disorder, panic disorder, social anxiety disorder, post-traumatic
stress disorder, attention deﬁcit hyperactivity disorder, bipolar disorder, schizophrenia, alcohol or drug use disorder and
personality disorder; somatic comorbidities included chronic fatigue syndrome, ﬁbromyalgia, neuropathic pain, irritable
bowel syndrome, hypertension, hypercholesterolemia, insomnia, obesity, migraine, diabetes, osteoarthritis, asthma, chronic
obstructive pulmonary disease, chronic pain, aches and pains, thyroid disorder and other
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than considered for (n = 447) an adjunctive
antipsychotic (54.3% versus 43.2%, P\0.05).
In both groups, MDD was considered to have a
great impact, for the majority of patients, on
social relationships (59.9% versus 55.7%) and
involvement in hobbies, interests or voluntary
work (56.0% versus 55.3%).
Factors Influencing Prescription
of an Adjunctive Antipsychotic
The most common reason given by physicians
for the actual prescription of an adjunctive
antipsychotic was better efficacy or symptom
control (52%, Fig. 1). Specific drug features that
were mentioned included non-sedative calming
(20%), sedation (16%), and activation (14%).
When physicians were asked to identify their
top three influences on the treatment decision,
the highest ranked factors overall were their
familiarity with or trust in the drug, the patient’s
level of functioning, a better tolerability profile,
and the patient’s history of MDD.
The most common reason that physicians
gave for not prescribing an adjunctive
antipsychotic or for not prescribing this
treatment earlier was a preference to wait to
see if the symptoms improved (1010/3538,
Fig. 1 Physician’s reasons for deciding to prescribe an
adjunctive antipsychotic. Drugs prescribed: aripiprazole
(n = 174), quetiapine XR (n = 103), quetiapine IR
(n = 96), olanzapine (n = 57), risperidone (n = 52), other
antipsychotic (n = 22), lurasidone (n = 12), iloperidone
(n = 1). Number of patients = 514; total number of drugs
prescribed = 517, two patients were each prescribed two
new adjunctive antipsychotics and one patient was
prescribed a new adjunctive antipsychotic and was switched
from a currently prescribed drug to an antipsychotic
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28.6%, based on the number of responses;
Fig. 2); this appeared to be driven by less
experienced physicians (611/1966, 31.1%)
more than experienced physicians (399/1572,
25.4%). Tolerability or safety concerns had
prevented or delayed prescription of an
adjunctive antipsychotic for 458/3538 patients
(12.9%) and again this was a greater concern for
less experienced physicians (280/1966, 14.2%
versus 178/1572, 11.3%). Tolerability was also
more of a concern for US than European
physicians (167/1018, 16.4% versus 291/2520,
11.6%). The physicians’ main concerns were
weight gain (275/458, 60.0%), other metabolic
side effects (264/458, 57.6%), extrapyramidal
symptoms (EPS; 198/458, 43.2%), sedation (146/
458, 31.9%), akathisia (117/458, 25.6%), and
prolactin-related side effects (100/458, 21.8%).
Symptoms Influencing Antipsychotic
Prescribing
Overall, 295/411 physicians (71.8%) indicated
for at least one of their patients that they
preferred to reserve antipsychotics for patients
with MDD who had specific symptoms. When
this group of physicians was asked which
symptoms they preferred to reserve
antipsychotics for, those symptoms most
frequently identified were: psychotic
symptoms (196/295, 66.4%), psychomotor
agitation (104/295, 35.3%), hostility (97/295,
32.9%), irritability (85/295, 28.8%), impulsivity
(83/295, 28.1%), and anger bursts (80/295,
27.1%; Fig. 3). These symptoms were relatively
consistently selected across regions: US
physicians identified their top symptoms as
Fig. 2 Physician’s reasons for not prescribing an adjunctive
antipsychotic in patients who were not considered for this
treatment and those who were considered but not
prescribed this treatment, and for not prescribing earlier
in those who were prescribed this treatment. Number of
responses = 3538, comprising data for 2577 patients who
were not considered for an adjunctive antipsychotic, 447
patients who were considered for but not prescribed this
treatment, and 514 patients who were prescribed this
treatment (i.e., reasons for not prescribing earlier). ADT
antidepressant treatment, AP antipsychotic, DDI drug–
drug interaction, MDD major depressive disorder
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psychotic symptoms (41/70, 58.6%), hostility
(27/70, 38.6%), psychomotor agitation (23/70,
32.9%), irritability (20/70, 28.6%), anger bursts
(19/70, 27.1%) and impulsivity (15/70, 21.4%),
with the same overall trends seen across the
European region as well.
Anxious mood and irritability were
mentioned more often as trigger symptoms by
physicians who actually prescribed adjunctive
antipsychotics to their survey patients than
those who did not (anxious mood: 14/60,
23.3% versus 15/235, 6.4%; irritability: 26/60,
43.3% versus 59/235, 25.1%). The most
frequently reported symptoms that actually led
to prescription or consideration of an adjunctive
antipsychotic for patients in the survey were
depressed mood (259/961, 27.0%) and anxious
mood (194/961, 20.2%; Fig. 4), which were
mostly rated as moderate or severe. Among
patients who were actually prescribed an
adjunctive antipsychotic, 87/514 (16.9%) had
two symptoms, and 200/514 (38.9%) had three
or more symptoms, that led to this prescription.
Differences were seen in the symptom profile
captured by coded and open formats; most
symptoms were mentioned less often in the
open format. In the coded format (symptom
checklist), the most frequently selected
symptoms were: depressed mood (47%),
anhedonia (31%), and anxious mood (31%). In
the open format (text box), the most frequently
mentioned symptoms were: anxious mood
(17%), psychotic symptoms (15%), and
depressed mood (14%). Of the 145 patients
who were prescribed an adjunctive
antipsychotic due to or partly due to anxious
mood, 24 (16.6%) also had a benzodiazepine
added to their treatment regimen.
Fig. 3 Physician’s indication of the symptoms that they
preferred to reserve antipsychotics for in patients with
MDD. Symptoms shown are those selected by C20% of
physicians. Number of responses = 295, comprising
physicians who indicated for at least one of their patients
that they preferred to reserve antipsychotics for patients
with MDD who had speciﬁc symptoms. MDD major
depressive disorder
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DISCUSSION
This case review study was conducted to
determine which patients with MDD and an
inadequate response to ADT are prescribed an
adjunctive antipsychotic and the key factors
that influence this decision. The study was
conducted in a real-world setting to provide
qualitative information on treatment decision
making in clinical practice across Europe and
the USA. The psychiatrists and primary care
physicians who participated in the study had
extensive experience in active clinical
management of patients with MDD. In
accordance with previous reports suggesting
that only 50–60% of patients with MDD
respond to first-line treatment [1], the
physicians estimated that around half of their
caseload of patients with MDD were not
responding adequately to their current
treatment regimen. Neither MDD diagnosis
nor inadequate responses were defined for the
physicians, to make this study as naturalistic as
possible, but the data gathered here provide
some interesting insights into what aspects of
patient presentation are associated with
physician perceptions of MDD and inadequate
response. Interestingly, among the patients
with MDD and an inadequate response to ADT
who were profiled for this study, around half
were already receiving combination therapy.
Augmentation or combination strategies are
recommended by treatment guidelines for
patients with MDD who experience partial or
no response to ADT [11]. Among strategies to
augment response with non-ADTs, adjunctive
second-generation antipsychotics are supported
by the strongest evidence [1]. In this study, a
treatment change involving an adjunctive
antipsychotic was considered for 23.9% of the
Fig. 4 Physician’s indication of symptoms that actually led
to consideration for, or prescription of, an adjunctive
antipsychotic in C10% of patients. *P\0.05 for considered
versus prescribed. Number of responses = 961, comprising
data for 447 patients who were considered for and 514
patients who were prescribed an adjunctive antipsychotic
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patients and actually made for 12.8%. Patients
who were prescribed adjunctive antipsychotics
had more severe disease than those who did not
receive this treatment, as evidenced by their
disease and treatment history, and CGI-S scores
both at initiation of treatment and the current
consultation. Consistent with this finding, a
retrospective study using data from patient
records reported that patients with severe
depression had an increased likelihood of
augmentation with second-generation
antipsychotics [10]. In our study, functional
impairment was also associated with adjunctive
antipsychotic prescribing. Although
employment status was similar in patients
who were considered for and prescribed
adjunctive antipsychotics, it is interesting that
the patients who were actually prescribed this
treatment tended to take more days off work
and to experience more time during which they
were unable to perform their daily tasks at the
usual level. It is noteworthy that physicians
considered MDD to have a great impact on
family relationships, social relationships and
involvement in hobbies, interests and voluntary
work, in more than half of the patients who
were prescribed adjunctive antipsychotics,
providing further evidence that functional
impairment guides the treatment decision
process.
The most common reason given by the
physicians for adjunctive antipsychotic
prescribing was to achieve better efficacy or
control of symptoms. Physicians who stated
that they reserved antipsychotics for patients
with specific symptoms indicated that key
triggers would be psychotic symptoms, and
arousal symptoms such as psychomotor
agitation, hostility, irritability, impulsivity,
and anger bursts. That those physicians who
reserved antipsychotic treatment were triggered
to add an antipsychotic by presence of
psychotic symptoms is perhaps not surprising,
but does raise the possibility that this is
uncovering the well-documented
underdiagnosis of bipolar spectrum disorder by
these physicians [12]. Anxious mood and
irritability were more likely to be mentioned
as trigger symptoms by physicians who actually
prescribed adjunctive antipsychotics to survey
patients than those who did not prescribe. For
the patients included in this survey,
unsurprisingly, moderate-to-severe depression
was a key influence on the treatment decision;
interestingly, moderate-to-severe anxiety was
also an important factor that led the physician
to consider adjunctive antipsychotics. It is
recognized that anxiety symptoms are
common in patients with MDD [13, 14] and
are associated with greater illness severity,
unfavorable course of illness, impaired
functioning, and poorer health-related quality
of life [15–17]. Other symptoms which led to
the prescription of an adjunctive antipsychotic
included core features of MDD such as insomnia
and anhedonia as well as irritability and
psychotic symptoms. More symptoms were
reported when the physician was provided
with a symptom checklist rather than an open
text box, which perhaps suggests that
physicians are considering a broad array of
issues with each patient, while focusing on key
symptoms for treatment decisions.
Current evidence supports the use of
adjunctive antipsychotics in patients with
MDD and an inadequate response to ADT [1,
8, 18]. Randomized, placebo-controlled clinical
studies have demonstrated significant
reductions in clinician-rated symptoms of
depression in patients with MDD who were
treated with adjunctive antipsychotics.
Augmentation with antipsychotics may be
effective in patients with an incomplete
response to ADT as well as in those who are
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treatment resistant. The biological rationale for
using adjunctive antipsychotics stems from the
broad receptor-binding profiles of these
medications at dopaminergic, noradrenergic,
and serotonergic receptors [1, 8]. For instance,
increased dopamine transmission in the
mesocortical dopamine pathway [8] may
explain the potential of these therapies to be
more effective than adding another ADT or
switching to a treatment with less profoundly
different binding profiles.
Obstacles to adjunctive antipsychotic
prescribing were also examined in this study.
Physicians indicated that they often preferred to
wait for a while to see if the symptoms improved
before prescribing an adjunctive antipsychotic.
Concern around the side effects of
antipsychotics was identified, particularly
regarding weight gain, related metabolic
effects, sedation, akathisia and EPS. It is
understandable that physicians may be
cautious in prescribing antipsychotics since it
is well known that certain drugs in this class are
associated with specific side effects, probably
linked to their pharmacological profile. For
example, quetiapine is associated with sedation
[19] and aripiprazole with akathisia [20].
Selection of an antipsychotic for an individual
patient should be guided by the patient’s clinical
characteristics and symptom profile.
This study has a number of limitations. It
should be noted that the data were not collected
as part of a prospective, controlled trial and the
survey responses were based on the physician’s
recent memory of the consultation and the
patient’s case notes. Many of the data collected
were estimated or categorical. Nevertheless, this
study provides real-world evidence of
physicians’ perceptions and clinical practice
patterns that cannot be determined in a
randomized, controlled trial.
CONCLUSIONS
This real-world case review study suggests that
the decision to prescribe an adjunctive
antipsychotic for a patient with MDD and an
inadequate response to ADT is influenced by a
broad spectrum of factors. Unsurprisingly,
physicians tended to reserve adjunctive
antipsychotics for patients with more severe
illness and greater functional impairment, and
those who had already failed a number of
treatment options. Consideration was also
given to the patient’s symptom profile. As well
as depressive features, symptoms such as
anxiety, psychotic symptoms, and irritability
were likely to prompt physicians to prescribe
adjunctive antipsychotics.
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